Global insurer Chubb Limited prepares to release its fourth-quarter financial results after Tuesday's market close, with investors weighing solid peer performances against broader sector headwinds.
While value investing promises bargains, some discounted stocks carry hidden risks. We examine three companies trading at low multiples but facing significant headwinds that warrant investor caution.
UK retail property specialist NewRiver REIT signals a resilient operational performance in its third quarter, driven by sustained consumer spending and strategic capital recycling, while navigating business rate changes.
While robust cash generation signals financial health, it doesn't guarantee stock outperformance. We analyze three cash-rich firms, highlighting one standout and two where strong cash flow masks underlying risks.
While strong cash generation is a hallmark of a healthy business, it doesn't guarantee success. We analyze one company reinvesting wisely for growth and two where caution may be warranted.
While strong cash generation is a hallmark of a healthy business, it doesn't automatically translate to a winning investment. We analyze three cash-rich companies, highlighting one that leverages its financial firepower effectively and two where cash flow alone may not be enough to justify investor optimism.
Havana denies White House accusations of being a security threat while appealing for constructive talks, as U.S. pressure cuts off vital Venezuelan oil supplies and risks a humanitarian crisis.
D-Wave Quantum Inc. announces a tenfold speed boost in missile defense simulations with partners Anduril and Davidson, alongside a $20M academic deal and a Fortune 100 QCaaS contract, signaling broader quantum computing integration.
Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.
Jacobs Solutions lands pivotal roles in California wastewater upgrades and UK nuclear project, reinforcing its position in sustainable infrastructure despite shares trading below analyst targets.
Mexican President Claudia Sheinbaum announces plans to send food and essential supplies to Cuba, vowing to pursue diplomatic channels for fuel shipments despite recent U.S. sanctions threats.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
A massive strike by public transport workers has brought buses and trams to a standstill across Germany, leaving commuters stranded in sub-zero temperatures as a bitter dispute over pay and conditions escalates.
Oracle Corporation announced a massive $45-50 billion fundraising plan for 2026, aiming to aggressively expand its cloud infrastructure to meet surging demand from leading AI and tech giants.
Energy Transfer LP announced a significant increase to its quarterly distribution alongside a multi-billion dollar capital expenditure plan for new pipeline and infrastructure projects, signaling confidence in its cash flow stability and long-term growth prospects.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Nepali authorities have arrested six executives from travel and rescue companies, alleging a sophisticated fraud scheme involving fabricated high-altitude rescues to bilk international insurers out of nearly $20 million.
A Russian drone attack on a bus carrying Ukrainian miners home from work has left at least 12 dead and 8 wounded, officials say, in what is being condemned as a deliberate strike on civilians.
As markets look ahead to 2026, a mix of established giants and emerging players in AI and digital advertising present compelling opportunities for investors seeking both growth and value.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
